Current Status of Drug Therapy for Chronic Hepatitis B
-
Published:2022
Issue:07
Volume:12
Page:6196-6201
-
ISSN:2161-8712
-
Container-title:Advances in Clinical Medicine
-
language:
-
Short-container-title:ACM
Publisher
Hans Publishers
Subject
General Engineering
Reference26 articles.
1. 中华医学会健康管理学分会, 中华医学会肝病学分会, 中华医学会检验医学分会. 病毒性肝炎健康管理专家共识(2021年) [J]. 中华健康管理学杂志, 2021, 15(4): 323-331.
2. 中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版) [J]. 实用肝脏病杂志, 2020, 23(1): 后插9-后插32.
3. Five-year efficacy and safety of tenofovir-based salvage therapy for patients with chronic hepatitis B who previously failed LAM/ADV therapy
4. 张晓强, 余建平, 盛吉芳. 替诺福韦与阿德福韦对慢性乙型肝炎患者肝功能、乙肝病毒载量及肝纤维化的临床疗效对比[J]. 中国药物应用与监测, 2021, 18(3): 147-149+164.
5. Synergistic Effect of Biejia-Ruangan on Fibrosis Regression in Patients With Chronic Hepatitis B Treated With Entecavir: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial